RetinalGenix Technologies contracts Seer Bio to advance early detection of neurodegenerative systemic and retinal diseases
I'm PortAI, I can summarize articles.
RetinalGenix Technologies Inc. has contracted Seer, Inc. to enhance early detection of neurodegenerative and retinal diseases. The collaboration will integrate RetinalGenix’s retinal imaging technology with Seer’s proteomic profiling platform to identify biomarkers for conditions like Alzheimer’s, Parkinson’s, and diabetic retinopathy. The partnership aims to accelerate diagnostic innovation and broaden early-detection solutions in clinical and home care settings.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments